A drug being tested against a liver disease thought to affect millions of people continues to hold up in a large clinical trial, according to its developer, New Jersey-based Intercept Pharmaceuticals.
The trial has enrolled thousands of patients with nonalcoholic steatohepatitis, or NASH, a disease characterized by a buildup of fat in the liver that progressively scars the organ. NASH is often asymptomatic until later stages, making it more difficult to diagnose. Yet, this “silent” disease has become one of the leading causes for liver transplants in the U.S.
Drug companies large and small have been spent more than a decade trying to develop the first approved treatment for NASH. In that race, Intercept and its candidate, known as obeticholic acid or OCA for short, have held a leading position.
In early 2019, OCA became the first drug to succeed in a Phase 3 study of NASH patients. The trial, named REGENERATE, enrolled participants with moderate to severe liver scarring, and found that a significantly greater percentage of those given a high dose of Intercept’s drug — as opposed to a placebo — had their liver scarring improve without their NASH getting worse. READ MORE
By Jacob Bell
Source: biopharmadive.com
After a contract manufacturing snafu in December, supply of Novo Nordisk’s GLP-1 med for obesity appears to be back on track in the U.S.—mostly. Novo’s Wegovy manufacturing partner—which the Danish company previously confirmed to Fierce Pharma as Catalent—restarted production on the med in 2022’s second quarter. As a result, 1.7-mg and 2.4-mg doses of Wegovy are back on tap in the U.S. market, Novo said in a recent investor report.
Once the offer is settled, CSL expects to get its hands on more than 97% of Vifor shares. At the same time, CSL plans to have Vifor apply for the delisting of its shares post-close. CSL has also filed an action to cancel remaining publicly held Vifor shares to satisfy Swiss takeover rules.
Amgen has signed a definitive agreement to acquire biopharmaceutical company ChemoCentryx for $52 for each share in cash or a total enterprise cost of nearly $3.7bn. ChemoCentryx focuses on orally administered therapeutics for the treatment of inflammatory disorders, autoimmune ailments and cancer.